Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?
Annals of Clinical Hypertension · 2021
DOI: 10.29328/journal.ach.1001025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Hypertension, 2021. Verfasst von Ergün Barış Kaya und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.
Zitieren
APA
Kaya, E. B., & Şener, Y. Z. (2021). Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?. Annals of Clinical Hypertension. https://doi.org/10.29328/journal.ach.1001025
Vancouver
Kaya EB, Şener YZ. Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?. Annals of Clinical Hypertension. 2021. doi:10.29328/journal.ach.1001025
BibTeX
@article{Kaya2021,
author = {Kaya, Ergün Barış and Şener, Yusuf Ziya},
title = {Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?},
journal = {Annals of Clinical Hypertension},
year = {2021},
doi = {10.29328/journal.ach.1001025}
}
EUVIMED